模型引导的临床前方法预测抗结核药物组合的临床药效学相互作用
该研究利用结核分枝杆菌体外时间杀菌实验,结合多状态结核药效学模型与通用药效学相互作用模型,在临床相关浓度下评估利福平、异烟肼和乙胺丁醇单用及联合的药效学相互作用。所有组合在菌落形成单位水平均显示相互作用,除异烟肼联合乙胺丁醇外均表现为协同;该建模方法能正确预测临床观察到的药效学相互作用。
要点
- MTP-GPDI模型可基于临床前信息预测抗结核药物组合的临床药效学相互作用。
- 除异烟肼联合乙胺丁醇外,其他测试组合在菌落形成单位水平均显示协同效应。
- 该模型方法为抗结核联合方案的早期开发与优化提供模型引导的输入。
核心结论
- 利用临床前信息,MTP-GPDI建模方法能够正确预测临床观察到的药效学相互作用,表现为偏离预期相加效应。
研究设计与样本
- 体外时间杀菌实验使用结核分枝杆菌,在临床相关浓度下测试利福平、异烟肼或乙胺丁醇单用及不同组合。
- 采用多状态结核药效学模型表征各药单药暴露后的自然生长与暴露-效应关系。
- 通过将MTP模型与通用药效学相互作用模型链接,分离联合药物对每种药物效力(EC50)的潜在影响。
主要发现
- 所有组合在菌落形成单位水平均显示药效学相互作用。
- 除异烟肼联合乙胺丁醇外,所有组合均显示比任何单药更强的效应(协同)。
- MTP-GPDI建模方法利用临床前信息正确预测了临床观察到的药效学相互作用。
临床怎么用
- 该模型方法可用于早期抗结核药物开发中预测临床药效学相互作用。
- 为新建和优化现有抗结核联合方案提供模型引导的输入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identification of pharmacodynamic interactions is not reasonable to carry out in a clinical setting for many reasons. The aim of this work was to develop a model-informed preclinical approach for prediction of clinical pharmacodynamic drug interactions in order to inform early anti-TB drug development. METHODS: In vitro time-kill experiments were performed with Mycobacterium tuberculosis using rifampicin, isoniazid or ethambutol alone as well as in different combinations at clinically relevant concentrations. The multistate TB pharmacometric (MTP) model was used to characterize the natural growth and exposure-response relationships of each drug after mono exposure. Pharmacodynamic interactions during combination exposure were characterized by linking the MTP model to the general pharmacodynamic interaction (GPDI) model with successful separation of the potential effect on each drug's potency (EC50) by the combining drug(s). RESULTS: All combinations showed pharmacodynamic interactions at cfu level, where all combinations, except isoniazid plus ethambutol, showed more effect (synergy) than any of the drugs alone. Using preclinical information, the MTP-GPDI modelling approach was shown to correctly predict clinically observed pharmacodynamic interactions, as deviations from expected additivity. CONCLUSIONS: With the ability to predict clinical pharmacodynamic interactions, using preclinical information, the MTP-GPDI model approach outlined in this study constitutes groundwork for model-informed input to the development of new and enhancement of existing anti-TB combination regimens.
引用
- Clewe O, Wicha SG, de Vogel CP, et al. A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations. J Antimicrob Chemother. 2018. PMID: 29136155. doi:10.1093/jac/dkx380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。